O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Watson AJ. et al, (2009), Br J Cancer, 100, 1250 - 1256
The metastatic niche: adapting the foreign soil.
Psaila B. and Lyden D., (2009), Nat Rev Cancer, 9, 285 - 293
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.
Sharma R. et al, (2009), Br J Cancer, 100, 707 - 712
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB. et al, (2009), Lancet, 373, 641 - 648
A phase i dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Scott EN. et al, (2009), Cancer Chemotherapy and Pharmacology, 64, 425 - 429
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors
Olmos D. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27
Role of Bone Microenvironment/Metastatic Niche in Cancer Progression
Podolanczuk A. et al, (2009), BONE AND CANCER, 89 - 101
Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma
Hatton CSR. et al, (2009), BRITISH JOURNAL OF HAEMATOLOGY, 145, 13 - 13
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Plummer R. et al, (2008), Clin Cancer Res, 14, 7917 - 7923
Dysregulation of Pax5 Activity Contributes to the Extinction of the B-Cell Phenotype in Reed-Sternberg Cells
Collins GP. et al, (2008), BLOOD, 112, 195 - 195
Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura
Bussel JB. et al, (2008), BLOOD, 112, 1176 - 1177
Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.
Lowndes SA. et al, (2008), Clin Cancer Res, 14, 7526 - 7534
Refractory immune thrombocytopenic purpura: current strategies for investigation and management.
Psaila B. and Bussel JB., (2008), Br J Haematol, 143, 16 - 26
ADJUVANT BEVACIZUMAB IS SAFE TREATMENT FOR MELANOMA PATIENTS AT HIGH RISK OF RECURRENCE
Biswas S. et al, (2008), ANNALS OF ONCOLOGY, 19, 245 - 245
FACTORS PREDICTING OUTCOME FOR ADVANCED GASTROESOPHAGEAL CANCER IN ELDERLY PATIENTS RECEIVING CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS
Lord SR. et al, (2008), ANNALS OF ONCOLOGY, 19, 210 - 210
IS CHEMOTHERAPY RE-CHALLENGE WORTHWHILE IN PATIENTS WITH RECURRENT GASTROESOPHAGEAL CANCER?
Hall PS. et al, (2008), ANNALS OF ONCOLOGY, 19, 171 - 171
Fc receptors in immune thrombocytopenias: a target for immunomodulation?
Psaila B. and Bussel JB., (2008), J Clin Invest, 118, 2677 - 2681
Fc receptors in immune thrombocytopenias: a target for immunomodulation?
Psaila B. and Bussel JB., (2008), JOURNAL OF CLINICAL INVESTIGATION, 118, 2677 - 2681
High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?
Leslie TA. et al, (2008), Br J Radiol, 81, 564 - 571